文献速递心脑血管急症

Absorb生物可吸收支架治疗冠心病的2年结局:七项随机试验的系统评价与荟萃分析及个体患者数据亚组研究

2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy.
PubMed 文献 · Lancet · 2017-07-18
一句话结论与金属依维莫司洗脱支架相比,Absorb生物可吸收支架在2年时及1至2年间设备导向复合终点和设备血栓发生率更高。

该研究为系统评价与荟萃分析,纳入7项随机试验共5583例患者,随机分配至Absorb BVS(n=3261)或金属EES(n=2322),随访2年。BVS组2年设备导向复合终点风险高于EES组(9.4% vs 7.4%;RR 1.29,95%CI 1.08-1.56,p=0.0059),主要由靶血管相关心肌梗死(5.8% vs 3.2%;RR 1.68,95%CI 1.29-2.19,p=0.0003)和缺血驱动的靶病变血运重建(5.3% vs 3.9%;RR 1.40,95%CI 1.09-1.80,p=0.0090)增加驱动,心源性死亡无显著差异。BVS组2年设备血栓累积发生率更高(2.3% vs 0.7%;RR 3.35,95%CI 1.96-5.72,p<0.0001)。1至2年界标分析同样显示BVS组设备导向复合终点(3.3% vs 1.9%;RR 1.64,95%CI 1.03-2.61,p=0.0376)和设备血栓(0.5% vs 0%,p<0.0001)更高。

要点

  • 与金属EES相比,Absorb BVS的2年设备导向复合终点风险更高(9.4% vs 7.4%;RR 1.29,95%CI 1.08-1.56,p=0.0059)。
  • BVS组2年靶血管相关心肌梗死风险更高(5.8% vs 3.2%;RR 1.68,95%CI 1.29-2.19,p=0.0003)。
  • BVS组2年设备血栓累积发生率显著更高(2.3% vs 0.7%;RR 3.35,95%CI 1.96-5.72,p<0.0001)。
  • 1至2年间BVS组设备导向复合终点(3.3% vs 1.9%;RR 1.64,95%CI 1.03-2.61,p=0.0376)和设备血栓(0.5% vs 0%,p<0.0001)仍更高。
  • BVS组与EES组心源性死亡差异无统计学显著意义。

适用人群与场景

  • 随机分配至everolimus洗脱Absorb BVS或金属everolimus洗脱支架(EES)并随访至少2年的冠心病患者,来自7项随机试验(共5583例:BVS n=3261,EES n=2322)。

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入7项随机试验,共5583例患者(BVS n=3261,EES n=2322),随访2年;个体患者数据来自4项ABSORB试验用于界标和亚组分析及多变量建模。
  • 主要疗效终点(设备导向复合终点:心源性死亡、靶血管相关心肌梗死或缺血驱动的靶病变血运重建)2年发生率:BVS组9.4%(304/3217) vs EES组7.4%(169/2299);RR 1.29(95%CI 1.08-1.56),p=0.0059。
  • 靶血管相关心肌梗死2年发生率:BVS组5.8%(187/3218) vs EES组3.2%(74/2299);RR 1.68(95%CI 1.29-2.19),p=0.0003。
  • 缺血驱动的靶病变血运重建2年发生率:BVS组5.3%(169/3217) vs EES组3.9%(90/2300);RR 1.40(95%CI 1.09-1.80),p=0.0090。
  • 心源性死亡:BVS组与EES组差异无统计学显著意义。
  • 主要安全终点(确定或可能的设备血栓)2年累积发生率:BVS组2.3%(73/3187) vs EES组0.7%(16/2281);RR 3.35(95%CI 1.96-5.72),p<0.0001。
  • 1至2年界标分析:设备导向复合终点BVS组3.3%(69/2100) vs EES组1.9%(23/1193);RR 1.64(95%CI 1.03-2.61),p=0.0376;设备血栓BVS组0.5%(11/2085) vs EES组0%(0/1183),p<0.0001。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入7项随机试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 与金属EES相比,Absorb BVS与2年累积及1至2年间设备导向复合不良事件和设备血栓发生率增加相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Bioresorbable vascular scaffolds (BVS) offer the potential to improve long-term outcomes of percutaneous coronary intervention after their complete bioresorption. Randomised trials have shown non-inferiority between BVS and metallic drug-eluting stents at 1 year in composite safety and effectiveness outcomes, although some increases in rates of target vessel-related myocardial infarction and device thrombosis were identified. Outcomes of BVS following the first year after implantation are unknown. We sought to ascertain whether BVS are as safe and effective as drug-eluting stents within 2 years after implantation and between 1 and 2 years.

METHODS: We did a systematic review and meta-analysis of randomised trials in which patients were randomly assigned to everolimus-eluting Absorb BVS or metallic everolimus-eluting stents (EES) and followed up for at least 2 years. We searched MEDLINE, the Cochrane database, TCTMD, ClinicalTrials.gov, Clinical Trial Results, CardioSource, and abstracts and presentations from major cardiovascular meetings up to April 1, 2017, to identify relevant studies. The primary efficacy outcome measure was the device-oriented composite endpoint (cardiac mortality, target vessel-related myocardial infarction, or ischaemia-driven target lesion revascularisation) and the primary safety outcome measure was definite or probable device thrombosis. Individual patient data from the four ABSORB trials were used for landmark and subgroup analysis and multivariable modelling.

FINDINGS: We identified seven randomised trials in which 5583 patients were randomly assigned to Absorb BVS (n=3261) or metallic EES (n=2322) and followed up for 2 years. BVS had higher 2-year relative risks of the device-oriented composite endpoint than did EES (9·4% [304 of 3217] vs 7·4% [169 of 2299]; relative risk [RR] 1·29 [95% CI 1·08-1·56], p=0·0059). These differences were driven by increased rates of target vessel-related myocardial infarction (5·8% [187 of 3218] vs 3·2% [74 of 2299]; RR 1·68 [95% CI 1·29-2·19], p=0·0003) and ischaemia-driven target lesion revascularisation (5·3% [169 of 3217] vs 3·9% [90 of 2300]; 1·40 [1·09-1·80], p=0·0090) with BVS, with non-significant differences in cardiac mortality. The cumulative 2-year incidence of device thrombosis was higher with BVS than with EES (2·3% [73 of 3187] vs 0·7% [16 of 2281]; RR 3·35 [95% CI 1·96-5·72], p<0·0001). Landmark analysis between 1 and 2 years also showed higher rates of the device-oriented composite endpoint (3·3% [69 of 2100] vs 1·9% [23 of 1193]; RR 1·64 [95% CI 1·03-2·61], p=0·0376) and device thrombosis (0·5% [11 of 2085] vs none [0 of 1183], p<0·0001) in BVS-treated patients than in EES-treated patients.

INTERPRETATION: BVS was associated with increased rates of composite device-oriented adverse events and device thrombosis cumulatively at 2 years and between 1 and 2 years of follow-up compared with EES.

FUNDING: Abbott Vascular.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Ali ZA, Serruys PW, Kimura T, et al. 2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet. 2017. PMID: 28732815. doi:10.1016/S0140-6736(17)31470-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。